全文获取类型
收费全文 | 743篇 |
免费 | 25篇 |
国内免费 | 91篇 |
专业分类
儿科学 | 6篇 |
妇产科学 | 7篇 |
基础医学 | 56篇 |
临床医学 | 34篇 |
内科学 | 290篇 |
神经病学 | 1篇 |
特种医学 | 7篇 |
外科学 | 14篇 |
综合类 | 111篇 |
预防医学 | 41篇 |
眼科学 | 1篇 |
药学 | 236篇 |
3篇 | |
中国医学 | 47篇 |
肿瘤学 | 5篇 |
出版年
2024年 | 1篇 |
2023年 | 3篇 |
2022年 | 4篇 |
2021年 | 14篇 |
2020年 | 13篇 |
2019年 | 18篇 |
2018年 | 20篇 |
2017年 | 16篇 |
2016年 | 36篇 |
2015年 | 44篇 |
2014年 | 101篇 |
2013年 | 88篇 |
2012年 | 88篇 |
2011年 | 77篇 |
2010年 | 56篇 |
2009年 | 35篇 |
2008年 | 32篇 |
2007年 | 34篇 |
2006年 | 44篇 |
2005年 | 33篇 |
2004年 | 16篇 |
2003年 | 20篇 |
2002年 | 11篇 |
2001年 | 15篇 |
2000年 | 7篇 |
1999年 | 9篇 |
1998年 | 5篇 |
1997年 | 2篇 |
1996年 | 4篇 |
1995年 | 3篇 |
1994年 | 4篇 |
1990年 | 3篇 |
1988年 | 1篇 |
1986年 | 2篇 |
排序方式: 共有859条查询结果,搜索用时 15 毫秒
61.
62.
为了评价干扰素、病毒唑、双黄连三药联合治疗小儿病毒性肺炎的疗效,将58例病毒性肺炎的患儿随机分为治疗组31例及对照组27例,治疗组采用干扰素肌注、病毒唑雾化吸入及双黄连静滴的方法.对照组于病毒唑单独静滴.结果治疗组总有效率明显高于对照组(x~2=7.39,P<0.01),治疗组退热时间明显短于对照组(P<0.05),平喘、止咳及肺部罗音吸收时间治疗组与对照组相比有非常显著差异(P<0.01),治疗组未见任何严重毒副作用.结果提示干扰素、病毒唑、双黄连三药联用治疗小儿病毒性肺炎为安全有效的方法. 相似文献
63.
《Annals of hepatology》2009,8(4):316-324
Background and Rationale. Anemia is a major side effect of combination therapy for chronic hepatitis C. In this study, severity, potential risk factors for and potential underlying mechanisms of anemia were evaluated.Patients and methods. 44 chronic hepatitis C patients on interferon-ribavirin treatment were included. Anemia-related parameters were measured before and during treatment. Potential changes in membrane phospholipids composition of erythrocytes of patients on anti-viral treatment and potentially increased erythrocyte susceptibility to osmotic or bile salt induced stress were explored.Results. Anemia was almost universal during treatment, with evidence of hemolysis. Decrease of Hb after six months of therapy was 2.1 ± O.I mmol/L (range -0.6-4.1). Higher pre-treatment Hb, highest ribavirin dose (1S-17.S mg/kg) and lower pre-treatment platelet level were independent risk factors for decrease of Hb. Serum erythropoietin levels increased during treatment with negative correlation to Hb levels at week 12 (r = -0.70, p = 0.002) and 24 (r = -0.72, p = 0.002). Erythrocyte membrane phospholipid composition did not differ between anemic patients and healthy controls. Also, resistance to osmotic or bile salt induced stress was normal in anemic patients. Phosphatidylserine exposure at the outer membrane leaflet did not change upon 24 hrs ex vivo incubation with pharmacological ribavirin concentration.Conclusions. Anemia is almost universal during anti-HCV treatment. The extent of anemia correlates with pre-treatment levels of thrombocytes and Hb and with high ribavirin dosing. Although we found hemolysis as contributing factor, our data do not indicate that altered membrane phospholipids composition is an important factor in pathogenesis of anemia. 相似文献
64.
病毒唑体外抑制RSV和ADV3作用强度的研究 总被引:3,自引:0,他引:3
目的:了角病毒唑在体外抑制呼吸道合胞病毒(RSV)和腺病毒3型(ADV3)的作用强度,对临床应用该药的理论依据进行验证,方法:采用观察Hep-2和Hela细胞病理变化方法,判断该药抗病毒作用的强度。结果:病毒唑在Hep-2和Hela细胞上完全抑制RSV和ADV3的剂量为7.8μg/ml。结论:在体外,小剂量的病毒唑有很强的抗RSV和ADV3的作用。 相似文献
65.
66.
67.
Motoo Y Mouri H Ohtsubo K Yamaguchi Y Watanabe H Sawabu N 《World journal of gastroenterology : WJG》2005,11(26):4013-4017
AIM: Ribavirin (RBV) shows a strong antiviral effect on hepatitis C virus when used in combination with interferon. However, RBV-induced anemia is a major problem in this therapy. It would be of great clinical importance to ameliorate the anemia without reducing the RBV dose. We report here that, Ninjinyoeito (NYT), a herbal medicine can reduce the RBV-induced anemia. METHODS: Twenty-three patients with chronic hepatitis C were treated with interferon alpha 2b plus RBV with (NYT group) or without (control group) NYT by a randomized selection. Eighteen patients completed the treatment schedule, and hemato-biochemical and virological effects were evaluated. RESULTS: There was no significant difference in biochemical and virological responses between the two groups. However, anemia was significantly reduced in the NYT group compared with the control group. The maximal decrease of Hb in the NYT group (2.59±1.10 g/dL) was significantly (P= 0.026) smaller than that in the control group (3.71±0.97 g/dL). There was no significant difference in serum glutathione peroxidase activity, serum RBV concentration, and Thl/Th2 balance between the two groups. There was no specific adverse effect in NYT administration. CONCLUSION: These results suggest that NYT could be used as a supportive remedy to reduce the RBV-induced anemia in the treatment of chronic hepatitis C. 相似文献
68.
Mosaburo Kainuma Norihiro Furusyo Eiji Kajiwara Kazuhiro Takahashi Hideyuki Nomura Yuichi Tanabe Takeaki Satoh Toshihiro Maruyama Makoto Nakamuta Kazuhiro Kotoh Koichi Azuma Junya Shimono Shinji Shimoda Jun Hayashi The Kyushu University Liver Disease Study Group 《World journal of gastroenterology : WJG》2010,16(35):4400-4409
AIM:To analyze the efficacy and safety of a combination therapy of pegylated interferon(PEG-IFN) α-2b plus ribavirin(RBV) in older Japanese patients(65 years or older) infected with hepatitis C virus(HCV).METHODS:This multicenter study included 938 patients with HCV genotype 1 who received 1.5 μg/kg per week PEG-IFN α-2b plus RBV 600-1000 mg/d for 48 wk and 313 HCV genotype 2 patients who received this treatment for 24 wk.RESULTS:At 24 wk after the end of combination therapy,the overall sustained virologica... 相似文献
69.
聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎疗效观察 总被引:1,自引:0,他引:1
朱松涛 《临床合理用药杂志》2011,(7):16-17
目的观察聚乙二醇干扰素(PEG-IFNα-2a)联合利巴韦林治疗慢性丙型肝炎的临床疗效。方法将53例慢性丙型肝炎患者随机分为2组,试验组28例给予PEG-IFNα-2a和利巴韦林治疗,对照组25例给予普通干扰素和利巴韦林治疗,疗程均为48周。随访24周,比较2组病毒学及生化应答情况。结果与对照组相比,试验组患者病毒学应答率明显升高,治疗结束病毒学应答(ETVR)和持续病毒学应答(SVR)率比较差异有统计学意义(P<0.05)。与治疗前相比,2组肝功能均明显改善;疗程结束及随访24周时,试验组仍保持较高的生化应答率(P<0.05)。结论 PEG-IFNα-2a联合利巴韦林治疗慢性丙型肝炎具有良好的病毒应答和生化应答,疗效优于普通干扰素。 相似文献
70.